NCT07625644
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07625644
Title BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
Acronym BrenDeLL-Lung01
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors SystImmune Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | POL | ITA | HUN | GRC | FRA | ESP | DEU | CZE | CAN | BGR | AUS


No variant requirements are available.